Regulatory Filing
Cipla Receives One USFDA Form 483 Observation Following Routine cGMP Inspection at InvaGen Facility
NSE
cipla
BSE
500087
- Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA)completed a routine Current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.
- The inspection concluded with one inspectional observation in Form 483, which the company has committed to address within the stipulated timeline.
PRICE-SENSITIVE TRIGGER
Event: Completion of USFDA cGMP Inspection at InvaGen Manufacturing Facility
Type: Regulatory Filing
Impact: Neutral
Immediate Effect: The USFDA concluded its routine cGMP inspection and issued one Form 483 observation. Cipla stated that it will work closely with the regulator to comprehensively address the observation within the prescribed timeframe.
highlight:
- USFDA inspection period: 13 July 2026 to 17 July 2026 (EDT)
- Facility: InvaGen Pharmaceuticals Inc., Central Islip, Long Island, New York, USA
- Inspection Outcome: One Form 483 observation issued upon completion of the inspection.
What Happened ?
Cipla informed the exchanges that the USFDA conducted a routine Current Good Manufacturing Practices (cGMP)inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of the company.
The inspection was conducted between 13 July 2026 and 17 July 2026 (EDT). At the conclusion of the inspection, the company received one inspectional observation in Form 483. Cipla stated that it will engage with the USFDA and implement appropriate corrective actions within the stipulated timeline.
key details – USFDA INspection
Inspection Details:
- Regulatory Authority: United States Food and Drug Administration (USFDA)
- Inspection Type: Routine Current Good Manufacturing Practices (cGMP) Inspection
- Inspection Period: 13 July 2026 – 17 July 2026 (EDT)
- Facility: InvaGen Pharmaceuticals Inc.
- Location: Central Islip, Long Island, New York, USA
Inspection Outcome:
- The inspection concluded with one Form 483 observation.
- No Warning Letter, Import Alert or Official Action Indicated (OAI) status has been disclosed.
- The company will work closely with the USFDA to address the observation comprehensively within the stipulated timeframe.
Strategic Importance:
- Routine USFDA inspections are an integral part of regulatory oversight for pharmaceutical manufacturing facilities supplying products to the U.S. market. Addressing inspectional observations promptly is important for maintaining regulatory compliance and uninterrupted manufacturing operations.
Note:
- The company has not disclosed the specific nature of the Form 483 observation or any expected financial or operational impact.
Risk Analysis
Summary:
- The inspection concluded with a single Form 483 observation. Based on the disclosure, there is no indication of regulatory enforcement action; however, successful and timely resolution of the observation will remain important.
Key Risks:
- The Form 483 observation requires corrective and preventive actions.
- Future regulatory reviews will depend on the adequacy of the company’s response.
- The nature of the observation has not been disclosed.
- Any delay in resolving regulatory observations could affect future compliance assessments.
Worst Case:
- If the observation is not addressed satisfactorily, future regulatory actions could impact manufacturing operations at the inspected facility.
Risk Level: Low
Company Commentary
- The inspection was a routine cGMP inspection.
- InvaGen Pharmaceuticals Inc. received one Form 483 observation at the conclusion of the inspection.
- Cipla will work closely with the USFDA.
- The company is committed to addressing the observation comprehensively within the stipulated timeline.
Official Exchange Filing: Cipla Limited
